NEW YORK (GenomeWeb News) – Traversa Therapeutics, a La Jolla, Calif.-based developer of RNAi delivery technologies, today announced that it has raised $2 million in a Series A financing round.
Traversa’s technology was developed by Steven Dowdy, a Howard Hughes Medical Institute investigator at the University of California, San Diego.
“The technology has received an outstanding level of interest for use with human therapeutics, and as a high-throughput screening reagent, providing the company with both long-term growth prospects and a short-term revenue stream to augment this financing,” Hans Petersen, president and CEO of Traversa, said in a statement.
The financing was led by San Diego Tech Coast Angels, with additional funding coming from Mesa Verde Venture Partners and Morningside Group.
The firm also said that Francois Ferre, co-CEO of Althea and lead angel investor, has joined its board.